Scarica l'app Stockscreener
90.25
3.14%
2.75
Dopo l'orario di chiusura:
90.85
0.60
+0.66%
Precedente Chiudi:
$87.50
Aprire:
$87.55
Volume 24 ore:
356.93K
Relative Volume:
0.69
Capitalizzazione di mercato:
$5.01B
Reddito:
$76.81M
Utile/perdita netta:
$-162.42M
Rapporto P/E:
-30.18
EPS:
-2.99
Flusso di cassa netto:
$-122.49M
1 W Prestazione:
+6.58%
1M Prestazione:
+9.93%
6M Prestazione:
+38.95%
1 anno Prestazione:
+7.10%
Intervallo 1D:
$86.84
$90.60
Intervallo di 1 settimana:
$84.54
$90.60
Portata 52W:
$47.86
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Nome
Arcellx Inc
Settore
Industria
Telefono
240-327-0603
Indirizzo
800 BRIDGE PARKWAY, REDWOOD CITY
Confronta ACLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
90.25 | 4.85B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-16 | Iniziato | Stifel | Buy |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-09-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-03-07 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-04 | Reiterato | Needham | Buy |
| 2023-12-19 | Iniziato | Scotiabank | Sector Outperform |
| 2023-10-30 | Iniziato | TD Cowen | Outperform |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-05-18 | Iniziato | Truist | Buy |
| 2023-04-14 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-14 | Iniziato | Stifel | Buy |
| 2023-02-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-13 | Ripresa | BofA Securities | Buy |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-10-27 | Iniziato | Needham | Buy |
| 2022-07-20 | Iniziato | Canaccord Genuity | Buy |
| 2022-03-01 | Iniziato | BofA Securities | Buy |
| 2022-03-01 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Arcellx Inc Borsa (ACLX) Ultime notizie
Arcellx, Inc. $ACLX Shares Sold by Pier Capital LLC - MarketBeat
What institutional flow reveals about Arcellx Inc.Portfolio Gains Report & Real-Time Sentiment Analysis - newser.com
Signal strength of Arcellx Inc. stock in tech scannersWeekly Earnings Recap & Weekly Top Gainers Trade List - newser.com
Trend analysis for Arcellx Inc. this weekOil Prices & Verified Technical Signals - newser.com
Fresh Analyst Optimism on CAR T-Cell Advances Might Change the Case for Investing in Arcellx (ACLX) - simplywall.st
Will Arcellx Inc. stock split again soon2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
Arcellx (ACLX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Using Python tools to backtest Arcellx Inc. strategiesJuly 2025 Short Interest & AI Optimized Trade Strategies - newser.com
Arcellx, Inc. (NASDAQ:ACLX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Arcellx, Inc. (ACLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
Is Arcellx Inc. stock a buy for dividend growthJuly 2025 EndofMonth & Fast Entry High Yield Stock Tips - newser.com
Arcellx Insiders Sell US$3.9m Of Stock, Possibly Signalling Caution - 富途牛牛
Canaccord Genuity Sticks to Their Buy Rating for Arcellx Inc (ACLX) - The Globe and Mail
Arcellx’s iMMagine-3 Study: A Potential Game-Changer for Multiple Myeloma Treatment - TipRanks
What drives Arcellx Inc stock priceEnergy Sector Updates & Minimal Capital Growth Ideas - earlytimes.in
Will Arcellx Inc. stock benefit from green energy trendsPortfolio Value Summary & Risk Controlled Stock Alerts - fcp.pa.gov.br
Arcellx Advances in Autoimmune Treatment with Anitocabtagene Autoleucel Study - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Arcellx Inc Azioni (ACLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):